PR Newswire02.26.18
Check-Cap Ltd., a clinical-stage medical diagnostics company engaged in the development of C-Scan, an ingestible capsule for preparation-free, colorectal cancer screening, announced the appointment of Alex Ovadia as CEO effective immediately. Prior to this appointment, Ovadia served as Check-Cap's COO, vice president of research and development and Israeli site manager since 2013. He succeeds William (Bill) Densel, who will provide support to complete a seamless transition.
Ovadia brings more than 25 years of experience leading global operations, in addition to worldwide management of complex projects at Philips Healthcare—CT Systems, as a member of Philips Medical Israel management, and at Elbit Systems, a large international defense company, where he held various positions with increased responsibilities.
Steven Hanley, Chairman of the Board of Directors of Check-Cap commented, "We are very pleased to announce the appointment of Alex Ovadia as CEO. We believe that Alex's leadership capabilities, global strategic perspective, and extensive R&D background will provide focus as we progress towards execution of our C-Scan commercial pathway. With our recent CE mark approval, a key validation of our breakthrough product, we look forward to Alex's leadership in driving the Company to achieve its mission of generating an alternative for colorectal cancer screening."
Alex Ovadia, CEO of Check-Cap stated, "I am very excited to take on the challenge of driving broad regulatory, clinical and commercial acceptance of our C-Scan product. Following our receipt in January of CE Mark, we continue to build a growing body of clinical evidence as we remain focused on bridging the gap toward the commercialization of C-Scan. We look forward to delivering on our target milestones and I am honored to continue to serve and further build with the talented and dedicated team at Check-Cap."
Ovadia brings more than 25 years of experience leading global operations, in addition to worldwide management of complex projects at Philips Healthcare—CT Systems, as a member of Philips Medical Israel management, and at Elbit Systems, a large international defense company, where he held various positions with increased responsibilities.
Steven Hanley, Chairman of the Board of Directors of Check-Cap commented, "We are very pleased to announce the appointment of Alex Ovadia as CEO. We believe that Alex's leadership capabilities, global strategic perspective, and extensive R&D background will provide focus as we progress towards execution of our C-Scan commercial pathway. With our recent CE mark approval, a key validation of our breakthrough product, we look forward to Alex's leadership in driving the Company to achieve its mission of generating an alternative for colorectal cancer screening."
Alex Ovadia, CEO of Check-Cap stated, "I am very excited to take on the challenge of driving broad regulatory, clinical and commercial acceptance of our C-Scan product. Following our receipt in January of CE Mark, we continue to build a growing body of clinical evidence as we remain focused on bridging the gap toward the commercialization of C-Scan. We look forward to delivering on our target milestones and I am honored to continue to serve and further build with the talented and dedicated team at Check-Cap."